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Long Term Uricosuric T-herapy in Gout 
By GEORGE R. THOMPSON, IVAN F. DUFF, WILLIAM D. ROBINSON, 
WILLIAM M. MIKKELSEN A D HENRIQUE GALINDEZ 
The effectiveness of long term uricosuric 
therapy was evaluated in sixty-four pa- 
tients with primary gout. Serum uric 
acid was reduced to normal in half the 
patients; the majority manifested a urate 
diuresis. In seventeen of fifty patients 
with tophi, these lesions decreased in 
size. Acute gouty attacks were reduced 
to less than one per year in forty-five, 
patients; the chronic symptoms present 
in fifty-one patients improved in forty., 
Effectiveness of therapy was categorized 
as good, moderate, and poor, with ex- 
amples of illustrative cases. 
Esseva evalutate le efficacia de therapia 
uricosuric a longe vista in 64 patientes 
con gutta primari. Le nivello sera1 de 
acido uric esseva reducite a1 nonna in 
un medietate del patientes; le majoritate 
manifestava diurese de urato. In 17 ex 
50 patientes con tophos, iste lesiones 
deveniva plus micre. In 45 patientes, 
le acute attaccos de gutta diminueva a 
minus que un per anno. Le symptomas 
chronic, presente in 51 patientes, se 
meliorava in 40. Le efficacia del therapia 
esseva classificate como bon, moderate, 
e non bon. Casos illustrative es citate. 
HE CONTROL of gout with uricosuric drugs became practical and ef- T fective with the introduction of probenecid in 1951.1*2 Since then addition- 
a1 potent uricosuric agents have been devel0ped,3-~ and the results with their 
use reported.1°-16 It is now established that gout is a disease of altered purine 
metabolism resulting in an increased body pool of uric acid.17-ls Unfortunately, 
these drugs do not correct the basic metabolic defect, nor do they exert an anti- 
inflammatory action (and hence are of no value in the management of acute 
gout). The goal of uricosuric therapy, therefore, is to create a negative mate 
balance by blocking renal tubular reabsorption of uric acid. 
This report deals with the effectiveness of long term uricosuric therapy in 
64 cases of primary gout. Specific indications for such treatment included: 
( 1) demonstrable tophi, (2) chronic gouty arthritis, and (3) hyperuricemia 
in excess of 8.0 mg. per cent. Recurrent, severe, and uncontrollable attacks 
of gout and the presence of renal urate calculi were considered to be relative 
indications. 
METHODS OF STUDY 
The uricosuric agents under investigation are listed in table 1. Since several patients 
received more than one drug during the course of the study, there were ninety-four sepa- 
rate experiences with individual uricosuric drugs. Most patients received maintenance doses 
of colchicine throughout the period of study. The diet was not specifically restricted, 
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Table 1.- Uricosuric Agents under Investigation 
No. of patient 
experiences* Usual dose 
Probenecid (Benemid) 53 1.5 Gm./day 
Sulfinpyrazone (Anturane) 15 300 mg./day 
Thiophenylpyrazolidine 7 800 mg./day 
Zoxazolamine ( Flexin) 11 500 mg./day 
Salicylates 4 5-6 Gm./day 
Combinations of above 4 
*AS several patients received more than one drug during period of follow-up, a total 
of 94 experiences with the various drugs was Obtained in these 64 patients. 
although most of the patients received instructions from a dietitian how to avoid foods 
with high purine content; caloric restriction was prescribed when indicated. 
Serum and urinary creatinine was measured by a modification of the method described 
by Bonsnes and TausskyFo the upper limit of serum creatinine in normal individuals 
being 1.5 mg. per cent. Serum and urinary uric acid was measured by a modification of 
the colorimetric method of Block and Geib.21 Blood was obtained in the nonfasting state. 
In this laboratory the upper limit of serum urate values for normal men is 6.0 mg. per 
cent; for women it is 5.5 mg. per cent. Urinary uric acid excretion was evaluated in terms 
of the ratio of urate clearance to creatinine clearance (U.C./Cr.C.) The value of this 
ratio as an expression of urate excretion is clarified if one considers first the creatinine 
clearance. By the fortuitous coincidence that the minimal amount of creatinine reabsorbed 
is approximately balanced by the amount excreted by the renal tubules, reabsorption can 
be considered nil, and the creatinine clearance equal to the glomerular filtration rate. 
With respect to uric acid, however, normally about 95 per cent of the filtered urate is 
reabsorbed in the proximal renal tubules, and only 5 to 10 per cent excreted.22~23 Thus 
the ratio of the urate clearance to the creatinine clearance expresses the per cent of the 
filtered uric acid that is ultimately excreted in the urine. Also, by this ratio, correction is 
possible for daily variations in urinary output. 
CLINICAL AND LABORATORY CHARACTERISTICS 
In this group of sixty-four patients, sixty of whom were male, the average 
age at the onset of gout was 36.7 years (table 2) .  The initial attack occurred 
before the age of 20 years in eight cases, between the ages of 20 and 40 years 
in thirty, and after the age of 40 years in twenty-six patients. The average age 
at the time uricosuric therapy was initiated was 49.7 years. Duration of total 
follow-up and duration of uricosuric therapy are shown in table 3. Twenty- 
two of these patients received uricosuric preparations for at least 3 years, and 
eleven were treated for 5 years or longer. 
The average serum urate concentration before treatment exceeded 8.0 mg. 
per cent in fifty patients (table 4). In forty-three patients, baseline ratios of 
urate clearance to creatinine clearance were obtained. In thirty-eight this ratio 
was under 10 per cent (within the normal range), but in three it was between 
10 and 15 per cent, and in two, between 16 and 20 per cent. 
In fifty of the patients tophi were known to be present at the onset of uri- 
cosuric therapy. Parotid duct calculi were proved in two patients and suspected 
in a third.24 Urinary tract calculi were present before treatment in five pa- 
tients (7.8 per cent). 
Five patients had diabetes mellitus, and one had two other metabolic de- 
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Table 2.-Age at Onset of Gout - 
No. of patients 
Less than 20 years 8 
4 0 4 9  years 18 
20-29 years 13 
30-39 years 17 
50-59 years 6 
2 60 years or over 
Total 64 
- 
Table 3.-Duration of Follow-up __ 
Duration 
At University On uricosurie 
Hospital drugs 





Over 90 months 







fects: hyperlipemia and glycogen storage disease (Von Gierke’s disease). 
Thirty patients showed blood pressure levels in excess of 150/100. Eight died 
during the period of follow-up, seven as the result of cardiovascular-renal 
disease, and the other of pneumonia. 
RESULTS OF URICOSURIC TREATMENT 
E f m t  on serum and urine urate ualues. The response to uricosuric agents 
was measured by the per cent decrease or fall in the average serum uric acid 
from the pretreatment value. It will be noted (table 4) that during the course 
of therapy in thirty-one patients the average serum uric acid value was re- 
duced to the normal range (6.0 mg. per cent or less). Furthermore, while fifty 
patients had average serum urate values over 8.0 mg. per cent prior to starting 
therapy, forty-nine showed a level below this value during uricosuric treatment. 
The serum urate response to individual drug preparations is shown in table 
5 and figure 1. A 30 to 45 per cent decline in serum uric acid occurred in 
twenty-three patients treated with probenecid, and in six of fifteen patients re- 
ceiving sulfinpyrazone. SalicyIates (5.0-6.0 Gm. per day) were found to be 
effective; however, because of eventual salicylism none of the patients was 
able to continue effective doses for prolonged periods of time. 
The effect of uricosuric drugs on urate excretion as measured by the urate 
a1earance:creatinine clearance ratio is seen in table 6 and figure 2. When one 
compares the baseline values with those on the various drugs, one sees that 
with each drug employed, the majority of patients experienced an increase in 
the U.C./Cr.C. ratio, manifesting a urate diuresis. An example of the changes 
in serum uric acid, urinary urate excretion, urate clearance and urate clear- 
ance: creatinine clearance ratio in an individual patient coincident with drug 
therapy is depicted in figure 3. 
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Table I.--Serum Urate Response to Uricosuric Theravu 
Average serum urate Before therapy On therapy 
No. of patients 
10.1 mg.% or greater 18 4 
8.1-10.0 mg.% 32 9 
7.1-8.0 mg.% 11 4 
6.1-7.0 mg.% 2 14 
6.0 or less 1 31 
Total 64 62 
Table 5.-Serum Urate Fall with Various Drugs 
16% or 46% or Total no. 
Drug leas* 16-29% 3 6 4 6 %  more patients 
Probenecid 11 18 23 1 53 ~ 
Sulfinpyrazone 3 4 6 2 15 
Thiophenylpyrazolidine 1 2 4 0 7 
Zoxazolamine 3 5 3 0 11 
Salicylates 0 2 2 0 4 
Combination of drugs 0 0 2 2 4 
Total-All drugs 18 31 40 5 94 
*Per cent lowering of serum uric acid from pretreatment values. 
Effect on tophi. There was evident diminution in size of tophi in seventeen 
of fifty patients (table 7 ) .  The mean serum urate value was 5.77 2 1.12 mg. 
per cent during treatment in the group in whom tophi decreased in size, as 
compared with a value of 7.07 f 1.82 mg. per cent in the group in whom this 
change did not occur; this difference, despite the rather large standard devia- 
tions, is thought to reflect a somewhat better response to therapy in the group 
with decreased tophi. Moreover, those whose tophi decreased in size were 
treated longer. If one considers cooperation in collection of 24 hour urine 
specimens as an index to the patient’s conscientiousness in adhering to the 
therapeutic program, there again appeared to be a slight difference in favor 
of the group whose tophi decreased in size. However, when the individual 
patient is considered, several persons noted for their conscientious adherence 
to details and who were followed for years did not demonstrate decrease in 
tophi in spite of an adequate lowering of serum uric acid levels. These results 
are in keeping with the concept that some tophi are sequestrated and not 
readily accessible to the body fluids. 
Efect on acute gout. In fifteen patients acute gout appeared to have been 
precipitated by initiation of uricosuric therapy in spite of concomitant main- 
tenance doses of colchicine. With perseverance, the acute attacks could 
usually be controlled and treatment continued. In two patients, however, this 
complication eventually prevented effective uricosuric therapy. 
Before treatment, twenty-four patients averaged six or more attacks of acute 
gout per year (table 8). After institution of therapy with daily maintenance 
doses of colchicine and uricosuric drugs, thirty-five patients experienced less 
than one attack per year (although in one patient the acute attacks were not 
controlled). 
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In twenty patients it was possible to evaluate the effects of colchicine alone 
on the frequency of acute gout. In fifteen of these there was a definite decrease 
in frequency of acute attacks, and in eleven there was a reduction to less than 
one attack per year. However, in five there was no marked improvement. In 
three patients there had been a decrease in frequency of attacks on colchicine 
alone, but with adequate uricosuric therapy there was an additional decrease 
to one attack or less per year. Other patients, in whom acute gout was well 
controlled on a regimen of both maintenance colchicine and uricosuric drugs, 
on stopping colchicine experienced a recurrence of acute gout. One patient, a 
physician, was able to stop colchicine without dif€iculty after several years on 
successful combined therapy. It is quite clear, however, that uricosuric drugs 
are of no value in the treatment of the acute attack of gout. Possibly a prophy- 
lactic effect may be associated with the establishment of increased urate ex- 
cretion and return of the serum urate toward normal. 
E2gect on gouty arthritis. Symptoms of chronic gouty arthritis, e.g., stiffness, 
joint soreness and aching, were present in fifty-one individuals. Upon institu- 
tion of therapy these symptoms improved in forty patients but were es- 
sentially unchanged in eleven. It is believed that these symptoms have their 
origin in tophaceous articular deposits, frequently with associated secondary 
osteoarthritic changes. Subacute gout may also contribute to the symptoms and 
is often improved on initiation of maintenance colchicine therapy. The toph- 
aceous component improves only slowly, being dependent on mobilization of 
deposited urates. 
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Table 6.-E%ect of Uricosuric Drugs on Urate Excretion 
No. of patients with urate clearance/creatinine 
clearance ratios of 
6% or 21% or 
Drup 1-6 610% 11-16% 1640% more 
Probenecid 0 13 19 10 1 
Sulfinpyrazone 1 2 8 4 1 
Thiophenylpyrazolidine 1 3 1 2 0 
Zoxazolamine 1 2 2 2 2 
Combination 0 0 1 1 2 
Baseline 11 27 3 2 0 
*Arrayed into groups of 5 per cent. 
Effect on the kidney. Seven patients experienced symptoms related to uri- 
nary tract calculi during uricosuric therapy, whereas five had had this com- 
plication before treatment. One patient experienced calculi before and after 
initiation of uricosuric drugs. Thus, in this series the incidence of renal calculi 
was essentially the same before and during uricosuric therapy. 
EFFECT OF DRUGS ON URIC ACED EXCWE'611OH 
BASELINE VALUES 
VALUES ON DRUG 
r -  z w 
( 6  6-10 11-15 16-20 )20 ( 6  6-10 11-15 16-20 )20 z -  
ZOXAZOLAMINE ( 8  patients) THIOPHENYWRAZOLIDINE (Spatlrnts) 1 
2 
( 6  6-10 11-15 16-20 )20 
J 2 
( 6  6-10 11-15 16-20 )20 
URATE CLEARANCE ICREATININE CLEARANCE IN % 
Fig. 2.-Comparison of the U.C./Cr.C. ratio before treatment and during treat- 
ment with various uricosuric drugs. The height of bars represents number of 
patients having U.C./Cr.C. ratios represented by that bar. 
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Fig. 3.-Response of serum and urinary urate, urate clearance, and U.C./Cr.C. 
ratio to uricosuric therapy in a selected case (L. G., No. 654006). 
In forty-four patients for whom pretreatment data were available, the renal 
status, in terms of serum creatinine and 24 hour endogenous creatinine clear- 
ance values, remained unchanged in thirty-five, grew worse in eight, and 
possibly improved in one during the course of therapy. The patient with ques- 
tionable improvement was a 26 year old white man (J. P., No. 858074) who 
had had severe tophaceous gout for 6 years; hematuria had been intermittent 
for several years. On initiation of uricosuric treatment, coincident with a severe 
attack of gout, the serum uric acid was 28.3 mg. per cent, the NPN was 97 
mg. per cent, and the creatinine clearance was 28 L. in 24 hours. There was 
one-plus albuminuria, and many red and white blood cells were present in the 
urinary sediment. The blood pressure was normal. There was no anemia. 
Pyelograms and renograms indicated multiple calculi, hydronephrosis, and 
markedly impaired function. With intensive treatment which included hospital- 
ization for 33 days, antibiotics, hydration, and protein restriction, in addition 
to uricosuric drugs, over a period of 2 months there was a decrease in the 
serum uric acid to about 11 mg. per cent, a gradual fall of the NPN to 32 mg. 
per cent, and a rise in the creatinine clearance to 113 L./% hours; the urine, 
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Table 7.-Compa&on of Response to Therapv in Fiftv Patients with Tophi 
Tophi smaller Tophi unchanged 
No. of patients 17 33 
Average serum urate 9.06 mg.% 9.76 me.% 
Average serum urate 6.77 mg.% 7.07 mg.% 
before treatment (range-7.06 to 11.36 mg.%) (range-6.47 to 22.32 mg.70) 
on treatment (range-3.62 to 7.93 mg.%) (range-4.6 to  11.2 mg.%) 
8 = 1.12 s = 1.82 
Average baseline urate 6.8% 6.7770 
excretion-measured (range-3.1 to 8.7%) (range--2.6 to 12.0%) 
by U.C./Cr.C. 
tion on therapy 
U.C./Cr.C. 
urine collections 
over 1 ?4 years 
Average urate exere- 13.3% 13.7370 
(range 3.17 to 31.770) (range 6.4 to 29.3%) 
Cooperation on 24 hour 88% 70% 
’% patients followed 69% 27% 
(16 to 17 patients) ( 23 of 33 patients ) 
~~ 
Table 8.-Eflect of Uricosuric Drugs and Colchicine on Attacks of Acute Gout 
Attacks per year Before therapy After therapy 
No. of patients 
1 or less per year 3 35 
2-5 23 14 
6-10 16 1 
11 or more 8 0 
Total 50 50 
aside from a trace of albumin, became normal. This favorable course was co- 
incident with subsidence of the acute gouty attacks. However, it should be 
emphasized that while improvement was concomitant with uricosuric treat- 
ment, it could not be dimctly attributed to it. “Reversal” of renal insufficiency 
in association with prolonged uricosuric therapy in a patient with tophaceous 
gout has been previously reported.25 
Untoward d e c k  With these uricosuric agents, nine patients developed 
gastrointestinal symptoms ( pyrosis, nausea, and vomiting) usually alleviated 
by taking the medication postprandially. Dermatitis medicamentosa was re- 
lated to probenecid in one patient and zoxazolamine in another. Although 
hepatic damage from these drugs has been reported,26v27 this complication was 
not encountered in our study. 
DISCUSSION 
The results of long term uricosuric therapy in gout may be classed as good, 
moderate, and poor. In our series good results were achieved in twenty-three 
individuals, about one-third of the total group; results were moderately suc- 
cessful in twentyeight or somewhat more than one-third; results were poor 
in thirteen or about one-fifth. 
Good results with uricomricr agents. Inclusion of a patient in this category 
implies successful control of acute attacks of gout, i.e., “clinical control,” and 
achievement of normal or near normal serum uric acid levels, i.e., “chemical 
control.” It is clear that the prerequisites for good results with uricosuric 
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agents include: (1) the careful indoctrination and strong motivation of a 
cooperative patient; ( 2 )  strict attention to all facets of treatment, with fre- 
quent adjustments of the program; and ( 3 )  the availability of reliable serum 
uric acid values. Details of two cases representative of this group follow: 
The first patient (L. G., No. 654006), a white man, developed gout at the age of 22 
years; before this, one kidney had been removed subsequent to a football injury. At the 
age of 40, when uricosuric therapy was initiated, he was subject to frequent, polycyclic 
attacks of gout, precipitated by fatigue, emotional tension, physical exertion, and change 
of seasons. Tophi were numerous and were rapidly enlarging. The serum uric acid varied 
from 10.6 to 9.3 mg. per cent; renal function was normal. Over the ensuing 7 years, with 
constant administration of various uricosuric agents plus maintenance colchicine, the 
attacks of acute gout ceased, tophi decreased in size, and the serum urate value declined 
to: 4.5 mg. per cent. In figure 3 the response of the serum uric acid, urinary urate excre- 
tion, urate clearance, and urate clearance: creatinine clearance ratio is graphically de- 
picted. Concomitant with this improvement, the patient has been able to return to normal 
physical activity enabling him to meet the demands of a busy and creative academic life. 
The second patient (L .  H., No. 645218), a white man, developed gout at the age of 19. 
When first seen, at the age of 30, he was crippled by severe heel-cord and hamstring con- 
tractures and by prominent gouty and osteoarthritic changes in the feet. For months, 
crutches had been required. He was experiencing multiple attacks of gout. Draining tophi 
were present. The average serum uric acid value was 10.9 mg. per cent. Treatment with 
probenecid was initiated, and although this was associated with the precipitation of acute 
gout, concomitant use of maintenance colchicine, supplemented occasionally with phenyl- 
butazone, eventually overcame the problem. Early in the course of therapy two episodes 
of ureteral colic occurred. After many months of treatment, and with the aid of selected 
physical therapeutic measures, he was able to walk without crutches. The tophi ceased to 
drain and decreased in size. The acute attacks of gout diminished in frequency. One and 
one-half years after initiation of this program of rehabilitation, the patient was able to 
assume a responsible job and became self-supporting. Now, 9 years later, the serum uric 
acid concentration is 4.2 mg. per cent. The patient has recently developed diabetes mel- 
litus. Interestingly enough, two brothers are subject to recurrent acute attacks of gout. 
His son, now 16 years of age, has also recently sustained an initial attack of gout and 
has hyperuricemia. 
Modmutely successful results with uricosuric agents. The twenty-eight pa- 
tients in this category may be divided into two groups. In the first were pa- 
tients with severe gout complicated by renal impairment. Six of the twenty- 
eight cases fell into this group. Despite their full cooperation in the diligent 
application of various drug regimens, only partial control of the disease was 
possible. While the frequency of attacks of acute gout were decreased. they 
were not eliminated; tophi did not decrease in size, although they were kept 
from enlarging. Serum urate levels were usually lowered but were not im- 
pressively reversed toward normal. The following case represents this group: 
The patient (L.  V., No. 800173), a white woman, probably developed podagra before 
the age of 20. In 1951, at  the age of 51 years, when reliable records were first available, 
hyperuricemia was present. By 1954, when she was first seen by us, many large and 
rapidly expanding tophi were present. The serum uric acid was 11.2 mg. per cent. There 
was slight azotemia,. the NPN being 53 mg. per cent, the serum creatinine 1.76 mg. per 
oent, and the creatinine clearance 43.1 ml. per minute. After surgical removal of a large 
tophus, -the patient was placed on a regimen including probenecid, dietary restriction, 
LONG TERM URICOSURIC THERAPY IN GOUT 393 
and colchicine. Initially, acute gout was controlled by the simultaneous administration of 
colchicine, phenylbutazone, and low doses of adrenocortical steroids; and eventually 
stabilization of the clinical course was achieved. With probenecid, however, the serum 
urate level was reduced by only about 5 per cent; with thiophenylpyrozolidine the 
average reduction was 20 per cent; with sulfinpyrazone, 17 per cent; and zoxazelamine, 
21 per cent. In the last 2 years of her life, a combination of agents was used, but the 
results were not notably superior to those with the individl;al preparations. Over a period 
of 7 years, although the tophi may have ceased to enlarge, they did not decrease in size. 
The acute attacks of gout, however, decreased in frequency. On the other hand, hyper- 
tension remained unchanged and the patient developed progressive renal failure and azo- 
temia [with a rise in blood urea nitrogen (BUN)  to 130. mg. per cent] which led even- 
tually to her death. 
In the second group in this category are included patients whose medical 
records are replete with missed appointments, omission of medication, and 
drug dosage obviously altered to the patient’s whims. In most of these patients 
the disease was mild. Nothwithstanding incomplete laboratory and clinical 
control, these patients were satisfied with the fact that the acute attacks had 
been rendered less frequent and tophus formation slowed or even halted. One 
such case follows: 
The patient (E. K., No. 66304l), a white male contractor, had experienced podagra 
at the age of 36. When he was 48 years old, uricosuric therapy was initiated because of 
obvious tophi and the occurrence of five or more acute, disabling attacks of gout per year. 
The serum urate level at that time averaged 8.18 mg. per cent. On a program of probenecid 
and colchicine, the serum uric acid promptly fell to a mean of 7.3 mg. per cent, with some 
values as low as 5.6 mg. per cent. This was associated with subsidence of the acute gouty 
attacks and possibly some decrease in tophus size. However, as return visits became more 
infrequent, and medication dosage became irregular, the serum uric acid rose to values in 
the neighborhood of 8 mg. per cent. At the time of his last visit, tophi were again ob- 
viously larger although the symptoms of acute and chronic gouty arthritis had not re- 
appeared. 
Urtsuccessful results. Those in whom control was unsuccessful were for the 
most part uncooperative individuals, some of whom were alcoholic. Character- 
istically the patients had acute gout when first seen. Although the initial treat- 
ment, usually in the hospital, was successful, soon after discharge on a program 
of uricosuric therapy the patients were lost to follow-up, only to return some 
years later with huge tophi, often severely crippled by their disease. In addi- 
tion, however, in a few patients we found it impossible to achieve a satisfactory 
uricosuric effect because of the precipitation of acute gout concomitant with 
initiation of uricosuric therapy, or because of idiosyncrasy to the drug em- 
ployed. Fortunately there are now available several potent uricosuric agents 
which can be used should idiosyncrasy to one occur. The two cases that fol- 
low represent these two reasons for lack of success: 
The first patient (B. K., No. 880156), a white man, was first seen at the age of 38 years. 
He had had gout since the age of 16 and was a confirmed alcoholic. Severe polycyclic at- 
tacks of gout of many week’s duration led to the initial hospitalization in 1957. The serum 
uric acid was 13.0 mg. per cent, and there were many tophi. Laennec’s cirrhosis and he- 
molytic anemia were present. With colchicine, phenylbutazone, and steroids the acute gout 
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Table 9.-Summary of Results of Treatment in Sixtyfour Cases of Primary Gout ___- 
% patients ~ _ _ _ _ _  
Improvement in chronic gout 98 
Decrease in acute gout to 1 attack per year 70 
Decrease in serum urate to normal 
Decrease in size of tophi 
Precipitation of acute gout by drugs 
Died during follow-up period 













cleared. Probenecid was then started. Over the 4 months’ period of hospitalization the 
serum urate fell to 8.3 mg. per cent (40 per cent decrease). The patient was discharged, 
much improved and able to return to work. Soon thereafter he was lost from the clinic. 
When heard from 3 years later, he had discontinued his medications and was again a 
chronic invalid with many tophi, repeated acute attacks of gout, and disabling chronic 
gouty arthritis. 
The second patient (R .  U., No. 764315), a 33 year old white man, had had gout for 8 
years. When first seen in 1953 he  had no tophi; the serum uric acid was 11.4 mg. per cent. 
With colchicine and oral steroids it was possible to control the acute attacks. During the 
18 months that he was carefully followed in our clinic, probenecid therapy was attempted 
on three separate occasions only to have acute gout develop within 3 days, leading to 
withdrawal of the drug. During this period repeated attacks of acute gout, uncontrolled by 
maintenance doses of colchicine, were accompanied by the appearance of tophi. As a further 
complication of therapy, there was dermatitis medicamentosa associated with phenyl- 
butazone. 
SUMMARY 
The effectiveness of long term uricosuric therapy was investigated in sixty- 
four patients (table 9 ) .  The drugs used included probenecid, sulfinpyrazone, 
thiophenylpyrazolidine, zoxazolamine, salicylates, and various combinations 
of these agents. 
The average age of the patients at the onset of gout was 36.7 years; the 
average age at the time of institution of uricosuric therapy was 49.7 years. 
The duration of treatment in twenty-two patients was over 36 months. Fifty 
had demonstrable tophi. 
In half the cases the serum urate level was reduced to normal (below 6.0 
mg. per cent). In thirty-five of fifty patients the number of acute attacks de- 
creased to one or less per year; and in forty of fifty-one patients, chronic gouty 
symptoms improved. In 17, the tophi decreased in size. 
To obtain complete control of the disease, dose cooperation must exist 
between the patient and the physician and reliable laboratory facilities must 
be available. Strict attention to details and individualization of patient care 
are required to achieve both clinical and laboratory control of this metabolic 
disease. Unfortunately, in forty-one of the patients in this series, the effect 
of prolonged uricosuric therapy proved to be only moderately successful or 
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poor, either because of the nature of the disease and its complications or 
certain factors inherent in the personality of the patient. 
CONCLUSIONS 
We are of the opinion that with the currently available therapeutic agents 
complete control of gout should be possible, provided the patient is com- 
pletely cooperative and renal function is adequate. This implies control of 
the acute attacks, chronic symptoms, and tophus formation. To achieve these 
goals, however, requires a dedicated, well informed, and enthusiastic physi- 
cian who will insist upon both “clinical control” (abolition of acute attacks) 
and “chemical control” (lowering of serum uric acid values to normal). 
ADDENDUM 
Since the completion of this study the drug zoxazolamine has been withdrawn from 
the market because of several reports of liver damage associated with use of this drug. In 
our series, there was no evidence of hepatic damage in the eleven patients who received 
the drug. 
ACKNOWLEDGMENTS 
The authors wish to express their appreciation of the technical assistance of Mr. Scott 
Himes, Mrs. Martha Albaugh, and Mrs. Elza Bryan. 
REFERENCES 
1. Gutman, A. B., and Yu, T. F.: Benemid 
as uricosuric agent in chronic gouty 
arthritis. Tr. Ass. Amer. Phys. 64: 
279, 1951. 
2. Sirota, J. H., Yu, T. F., and Gutman, 
A. B.: Effect of benemid on urate 
clearance and other discrete renal 
function tests in gouty subjects. J. 
Clin. Invest. 31:692, 1952. 
3. Bums, J. J., Yu, T. F., Ritterband, A., 
Perel, J. M., Gutman, A. B., and 
Brodie, B. B.: A potent new uricosuric 
agent, the sulfoxide metabolite of the 
phenylbutazone analogue G25671. J. 
Pharm. and Exp. Therapeutics 119: 
418, 1957. 
4. Brodie, B. B., Yu, T. F., Bums, J. J., 
Chenkin, T., Paton, B. C., Steele, J. 
M., and Gutman, A. B.: Observa- 
tions on G25671, a phenylbutazone 
analogue. Proc. SOC. Exper. Biol. & 
Med. 86:884, 1954. 
5. Reed, E. G., Feichtmeir, T.’V., and Wil- 
lett, F. M.: Zoxazolamine, a potent 
uricosuric agent. New England J. 
Med. 258:394, 1958. 
6. Burns, J. J., Yu, T. F., Berger, L., and 
Gutman, A. B.: Zoxazolamine, physio- 
logical disposition and uricosuric 
properties. Am. J. Med. 25:401, 1958. 
7. Marson, F. G. W.: Effect of ACTH and 
sodium salicylate on the urinary 
uric acid: creatinine ratio, and cir- 
culating eosinophils in man. Ann. 
Rheumat. Dis. 12:296, 1953. 
8. -: Sodium salicylate and probenecid in 
the treatment of chronic gout. Ann. 
Rheumat. Dis. 13:233, 1954. 
9. Seegmiller, J. E.: Role of the newer 
uricosuric agents in management of 
gout. Bull. Rheumat. Dis. 11:241, 
1961. 
10. Gutman, A. B., and Yu, T. F.: Pro- 
tracted uricosuric therapy in toph- 
aceous gout. Lancet 2:1258, De- 
cember 21, 1957. 
11. Ogryzlo, M. A., and Harrison, J.: Eval- 
uation of uricosuric agents in chronic 
gout. Ann. Rheumat. Dis. 16:425, 
1957. 
12. Smyth, C. J., Frank, L. S., and Hoff- 
man, E.  R.: Urate diuretic therapy in 
chronic gout. Arch. Interamer. Rheu- 
mat. 3:3, 1960. 
13. Bartels, E. C., and Matossian, G. S . :  
Gout, six-year follow-up on pro- 
396 THOMPSON, DUFF, ROBINSON, MIKKELSEN AND GALINDEZ 
benecid (benemid) therapy. Arth. 
and Rheumat. 2:193, 1959. 
14. Kersley, G. D., and Gibbs, A. R.: Uri- 
cosuric agents in the treatment of 
gout. Ann. Rheumat. Dis. 19:351, 
1960. 
15. Talbott, J. H.: Current concepts of gout. 
Arch. Interamer. Rheumat. 1:81, 
1958. 
16. -: Gout and Gouty Arthritis. Modem 
Medical Monographs; New York, 
Grune and Stratton, 1953. 
17. Gutman, A. B.: Some recent advances 
in the study of uric acid metabolism 
and gout. Bull. New York Acad. Med. 
27: 144, 1951. 
18. Smyth, C. J. et al: The uric acid prob- 
lem-Thirteenth rheumatism review. 
Ann. Int. Med. 53:144, 1960. 
19. Seegmiller, J. E., Grazel, A. I., Laster, 
L., and Liddle, L.: Uric acid produc- 
tion in gout. J. Clin. Invest. 40:1304, 
1961. 
20. Bonsnes, R. W., and Taussky, H. H.: 
On the colorimetric determination of 
creatinine by the Jaffe reaction. J. 
BioI. Chem. 158:581, 1945. 
21. Block, W. D., and Geib, N. C.: An 
enzymatic method for the determina- 
tion of uric acid in whole blood. J. 
Biol. Chem. 168:747, 1947. 
22. Gutman, A. B., and Yu, T. F.: Renal 
regulation of uric acid excretion in 
normal and gouty man: modification 
by uricosuric agents, Bull. New York 
Acad. Med. 34:287, 1958. 
23. -, and Yu, T. F.: Renal function in 
gout. Am. J. Med. 23:600, 1957. 
24. Blatt, I. M., Mikkelsen, W. M., and 
Denning, R. M.: Studies in sialoli- 
thiasis 11. Uric acid calculus of the 
parotid gland: Report of a case. Ann. 
Otol. Rhin. & Laryng. 67:1022, 1958. 
25. Phillips, R. W.: Reversal of renal in- 
sufficiency in gout. A. M. A. Arch. 
Int. Med. 96:823, 1955. 
26. Reynolds, E. S., Schlant, R. C., Gonich, 
H. C., and Dammin, G. J.: Massive 
necrosis of the liver as a manifestation 
of hypersensitivity to probenecid. New 
England J. Med. 256:592, 1957. 
27. Carr, H. J., and Khauer, Q.  F.: Death 
due to hepatic necrosis in a patient 
receiving zoxazolamine: Report of a 
case and review of the literature. New 
England J. Med. 264:977, 1961. 
George R. Thompson, M.D., Fellow, Department of Internal 
Medicine and the Rackham Arthritis Researoh Unit, The 
University of Michigan. 
Ivan F .  Duff, M.D., Professor, Depwtmtmt of Internal Medi- 
cine, in Charge of Rackham Arthritis Research Unit, The 
University of Michigan. 
William D.  Robinson, M.D., Professor and. Chairman., De- 
partment of Internal Medicine, The University of Michigan. 
William M .  Mikkelsen, M.D., Assolciate Professor, Depart- 
ment of Internal Medicine, The University of Michigan. 
Henrique Galindez, M.D., Fellow, Rackhum Arthritis Re- 
search Unit 1954-1955; Assok te  Professor of Physiology, 
The Universidad Central de Venezuela. 
